Health
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
Publication: STAT
Author: Ed Silverman
Source published: 02/10/2026, 13:11:16 UTC
Briefing created: 03/10/2026, 03:18:54 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/10/2026, 03:07:24 UTC.
Briefings
A 2026 article reports on Boehringer Ingelheim's obesity drug achieving a 13.1% weight loss in diabetes patients, which Bloomberg described as disappointing. The text notes the drug faces competition from Eli Lilly and Novo, with Boehringer pushing back via future heart and liver studies. It also covers upcoming midterm elections affecting Senate health committees and Novartis's $7.8 billion licensing deal with Chinese biotech Abogen for an RNA-based therapy targeting autoimmune diseases.
Key points
- Boehringer Ingelheim's obesity drug achieved a 13.1% weight loss in diabetes patients, a result Bloomberg News labeled disappointing.
- Novartis signed a licensing deal worth $7.8 billion with Chinese biotech Abogen to advance an RNA-based therapy for autoimmune diseases.
Context and limitations
This briefing covers only the obesity drug results, Senate committee changes, and the Novartis licensing deal. It does not include data on other pharmaceuticals, specific patient demographics, or future study outcomes.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/10/2026, 03:18:54 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeid5sjef6cwtjc3ftmv2l2nxxcr2peek77htgmsmlih3twaztdkbxe